Genfit SA and Sanofi SA Update on Collaboration Regarding Adaptation to Stress


Tuesday, 22 Jan 2013 01:00am EST 

Genfit SA and Sanofi SA announced the demonstration of the activity of several chemical series, selected as part of the second approach of their research program. The achievement of this second step follows on from the first one in April 2012, in the context of the research contract signed in March 2011 for a period of three years, during which SANOFI and GENFIT are committed to working together on the discovery and development of new drug candidates targeting several metabolic disorders. With this demonstration, a second scientific foundation stone is thus placed for one of the approaches of this research program targeting mitochondrial dysfunction. These results confirm the hypothesis, formulated in early 2011 on the basis of clinical observations, that the adaptation to stress of cellular mechanisms regulating energy production offers a therapeutic potential in numerous pathologies including metabolic diseases. In accordance with the terms of the contract, whereby SANOFI obtained the exclusive worldwide rights to develop and commercialize the molecules arising from the research collaboration, GENFIT has received the second part of payments included in the agreement. Depending on the preclinical and clinical development, and the subsequent registration and commercialization of resulting products, the total of the payments included in the agreement could reach USD 54.5 million (EUR 39 million). 

Company Quote

74.99
-0.65 -0.86%
24 Dec 2014